Antony Loebel

9.2k total citations · 2 hit papers
226 papers, 6.4k citations indexed

About

Antony Loebel is a scholar working on Psychiatry and Mental health, Clinical Psychology and Pharmacology. According to data from OpenAlex, Antony Loebel has authored 226 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 198 papers in Psychiatry and Mental health, 35 papers in Clinical Psychology and 34 papers in Pharmacology. Recurrent topics in Antony Loebel's work include Bipolar Disorder and Treatment (122 papers), Schizophrenia research and treatment (117 papers) and Electroconvulsive Therapy Studies (47 papers). Antony Loebel is often cited by papers focused on Bipolar Disorder and Treatment (122 papers), Schizophrenia research and treatment (117 papers) and Electroconvulsive Therapy Studies (47 papers). Antony Loebel collaborates with scholars based in United States, United Kingdom and Japan. Antony Loebel's co-authors include Josephine Cucchiaro, Jeffrey A. Lieberman, Robert Silva, David Mayerhoff, Cynthia Siu, S. Szymanski, Philip D. Harvey, Stephan Geisler, José Alvir and Kaushik Sarma and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Antony Loebel

218 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Duration of psychosis and outcome in first-episode schizophrenia

1992 663 citations Antony Loebel et al. profile →
A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia

2020 204 citations Kenneth S. Koblan, Justine Kent et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Antony Loebel United States	41	5.3k	1.1k	1.1k	829	670	226	6.4k
Myrto Samara Germany	25	4.0k 0.8×	855 0.8×	969 0.9×	733 0.9×	462 0.7×	80	5.9k
Larry Alphs United States	36	3.8k 0.7×	921 0.8×	1.1k 1.0×	937 1.1×	586 0.9×	174	5.2k
Robert Lasser United States	33	3.4k 0.6×	927 0.8×	1.0k 0.9×	1.1k 1.3×	408 0.6×	94	4.8k
William H. Carson United States	52	7.0k 1.3×	1.9k 1.7×	1.5k 1.4×	742 0.9×	689 1.0×	141	8.8k
Brian Sheitman United States	33	4.6k 0.9×	535 0.5×	1.7k 1.5×	1.2k 1.4×	681 1.0×	87	6.0k
Bruce J. Kinon United States	47	5.0k 1.0×	845 0.7×	1.1k 1.0×	789 1.0×	1.3k 1.9×	153	7.4k
Alexander L. Miller United States	44	3.7k 0.7×	719 0.6×	1.1k 1.0×	962 1.2×	552 0.8×	145	6.0k
Ofer Agid Canada	42	4.0k 0.8×	553 0.5×	1.2k 1.2×	1.1k 1.3×	875 1.3×	135	5.9k
Philippe Conus Switzerland	52	5.3k 1.0×	713 0.6×	2.4k 2.2×	1.0k 1.3×	682 1.0×	307	8.5k
Ronald N. Marcus United States	42	5.2k 1.0×	1.4k 1.3×	1.2k 1.1×	298 0.4×	487 0.7×	87	6.5k

Countries citing papers authored by Antony Loebel

Since Specialization

Citations

This map shows the geographic impact of Antony Loebel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antony Loebel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antony Loebel more than expected).

Fields of papers citing papers by Antony Loebel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antony Loebel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antony Loebel. The network helps show where Antony Loebel may publish in the future.

Co-authorship network of co-authors of Antony Loebel

This figure shows the co-authorship network connecting the top 25 collaborators of Antony Loebel. A scholar is included among the top collaborators of Antony Loebel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antony Loebel. Antony Loebel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Szabo, Steven T., Seth C. Hopkins, Robert Lew, et al.. (2023). A multicenter, double-blind, placebo-controlled, randomized, Phase 1b crossover trial comparing two doses of ulotaront with placebo in the treatment of narcolepsy-cataplexy. Sleep Medicine. 107. 202–211. 5 indexed citations

Perini, Francesca, Shane McKie, Liliana Capitão, et al.. (2023). Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy. SHILAP Revista de lepidopterología. 9(1). 49–49. 3 indexed citations

Goldberg, Joseph F., et al.. (2023). The Effect of Lurasidone on Anxiety Symptoms in Patients With Bipolar Depression. The Journal of Clinical Psychiatry. 84(4). 3 indexed citations

Hopkins, Seth C., et al.. (2022). Assessment of Negative Symptoms in Clinical Trials of Acute Schizophrenia: Test of a Novel Enrichment Strategy. Schizophrenia Bulletin Open. 3(1). 7 indexed citations

Mattingly, Gregory W., Peter Haddad, Michael Tocco, et al.. (2020). Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study. BMC Psychiatry. 20(1). 199–199. 14 indexed citations

Koblan, Kenneth S., Seth C. Hopkins, Justine Kent, et al.. (2020). 138 Efficacy and Safety of SEP-363856, a Novel Psychotropic Agent with a Non-D2 Mechanism of Action, in the Treatment of Schizophrenia. CNS Spectrums. 25(2). 287–288. 6 indexed citations

Findling, Robert L., Lenard A. Adler, Thomas Spencer, et al.. (2019). Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial. Journal of Child and Adolescent Psychopharmacology. 29(2). 80–89. 29 indexed citations

Clayton, Anita H., et al.. (2018). Effect of Lurasidone on Sexual Function in Major Depressive Disorder Patients With Subthreshold Hypomanic Symptoms (Mixed Features). The Journal of Clinical Psychiatry. 79(5). 9 indexed citations

Swann, Alan C., et al.. (2017). Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis. CNS Spectrums. 22(2). 228–235. 11 indexed citations

10.

Goldberg, Joseph F., Daisy Ng‐Mak, Cynthia Siu, et al.. (2017). Remission and recovery associated with lurasidone in the treatment of major depressive disorder with subthreshold hypomanic symptoms (mixed features): post-hoc analysis of a randomized, placebo-controlled study with longer-term extension. CNS Spectrums. 22(2). 220–227. 9 indexed citations

11.

Chu, Bong-Chul, et al.. (2016). Adherence to Lurasidone and other Atypical Antipsychotics among Patientswith Bipolar Disorder: A Real World Assessment. 2(2). 2 indexed citations

12.

Patkar, Ashwin A., Chi‐Un Pae, Paul A. Vöhringer, et al.. (2015). A 13-Week, Randomized Double-Blind, Placebo-Controlled, Cross-Over Trial of Ziprasidone in Bipolar Spectrum Disorder. Journal of Clinical Psychopharmacology. 35(3). 319–323. 11 indexed citations

13.

Ereshefsky, Larry, et al.. (2014). Lurasidone drug-drug interaction studies: a comprehensive review. Drug metabolism and drug interactions. 29(3). 191–202. 29 indexed citations

14.

Hassan, Mariam, et al.. (2013). Hospitalizations among bipolar disorder patients before and after initiating lurasidone in a commercially insured population. Value in Health. 16(3). A68–A68. 1 indexed citations

15.

Citrome, Leslie, Terence A. Ketter, Josephine Cucchiaro, & Antony Loebel. (2013). Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders. 155. 20–27. 60 indexed citations

16.

Patkar, Ashwin A., William Gilmer, Chi‐Un Pae, et al.. (2012). A 6 Week Randomized Double-Blind Placebo-Controlled Trial of Ziprasidone for the Acute Depressive Mixed State. PLoS ONE. 7(4). e34757–e34757. 48 indexed citations

17.

Potkin, Steven G., Masaaki Ogasa, Josephine Cucchiaro, & Antony Loebel. (2011). Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophrenia Research. 132(2-3). 101–107. 43 indexed citations

18.

Meyer, Jonathan M., Antony Loebel, & Edward E. Schweizer. (2009). Lurasidone: a new drug in development for schizophrenia. Expert Opinion on Investigational Drugs. 18(11). 1715–1726. 110 indexed citations

19.

Dünner, David L., Jay D. Amsterdam, Richard C. Shelton, Antony Loebel, & Steven J. Romano. (2007). Efficacy and Tolerability of Adjunctive Ziprasidone in Treatment-Resistant Depression. The Journal of Clinical Psychiatry. 68(7). 1071–1077. 56 indexed citations

20.

Citrome, Leslie, Jan Volavka, Pál Czobor, et al.. (2006). Efficacy of Ziprasidone Against Hostility in Schizophrenia. The Journal of Clinical Psychiatry. 67(4). 638–642. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact